AXDX

Accelerate Diagnostics Schedules Call to Review 2nd Quarter 2021 Results

Up 6% in June, Is Accelerate Diagnostics a Good Buy Now?

Accelerate Diagnostics Launches a Fast Antimicrobial Susceptibility Test for Use with Existing ID Systems in the United States

New Accelerate Pheno® Landmark Study Validates Important Clinical Benefits to Be Presented at ECCMID 2021

Accelerate Diagnostics to Participate in William Blair 41st Annual Growth Stock Conference on June 3, 2021

Accelerate Diagnostics, Inc. (AXDX) CEO Jack Phillips on Q1 2021 Results - Earnings Call Transcript

Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates